83101-15-9

Upstream product

• 83101-13-7 3-(3-cyanophenyl)-1-propanol 
• 603-35-0 triphenylphosphine 
• 558-13-4 carbon tetrabromide 
• 42287-97-8 3-(3-cyanophenyl)propanoic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 52273-78-6 γ-(3-Aminophenyl)propanol 
• 1504-76-3 3-nitrocinnamaldehyde 
• 1504-64-9 3-(3-nitrophenyl)prop-2-en-1-ol 

Downstream Products

• 83101-80-8 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-76-2 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-92-2 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-benzamidine; hydriodide 
• 83116-31-8 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-benzamidine; hydriodide 
• 83101-71-7 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-72-8 3-[4-Phenylcarbamoyl-4-(toluene-4-sulfonylamino)-butyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-85-3 5-(3-Carbamimidoyl-phenyl)-2-(toluene-4-sulfonylamino)-pentanoic acid phenylamide; hydriodide 
• 83101-84-2 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-benzamidine; hydriodide 
• 83101-67-1 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-63-7 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-54-6 5-(3-Cyanphenyl)-2-β-naphthylsulfonylaminovaleriansaeuremorpholid 
• 83101-50-2 5-(3-Cyanphenyl)-2-α-naphthylsulfonylaminovaleriansaeuremorpholid 
• 83101-59-1 5-(3-Thiocarbamoyl-phenyl)-2-(toluene-4-sulfonylamino)-pentanoic acid phenylamide 
• 83101-58-0 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-thiobenzamide 

Relevant academic research and scientific papers

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES

New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of the following formulae or analogs thereof, i. e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants.

1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute